Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | PI4KA | P42356 | 5/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385353 | 0.75 | ADORA2A (0.37) | ADORA2A | |
| SCHEMBL11205177 | 0.71 | LMNA (0.39) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL314773 | 0.70 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL4573957 | 0.70 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL28188932 | 0.70 | ADORA2A (0.37) | ADORA2A | |
| SCHEMBL23618574 | 0.70 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL8082857 | 0.70 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL314774 | 0.70 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL2007373 | 0.70 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL27300372 | 0.70 | PIK3CG (0.49) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101257948-A | Pyrimidine-fused diazepine derivatives and indole-fused pteridines | ATTENUON LLC (US) | 2008-09-03 | — | — | CN | claimed |
| EP-0399856-B1 | Pteridin-4 (3H)-ones, processes for their preparation and medicaments containing them | LIPHA (FR) | 1995-08-09 | — | — | EP | claimed |
| US-5167949-A | Antiallergic | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1992-12-01 | — | — | US | claimed |
| EP-0399856-A1 | Pteridin-4 (3H)-ones, processes for their preparation and medicaments containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1990-11-28 | — | — | EP | claimed |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-04-21 | — | — | US | disclosed |
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2026-02-10 | — | — | US | disclosed |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2022-07-28 | — | — | US | disclosed |
| EP-3976609-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | disclosed |
| CN-114222741-A | As P2X3Suppression ofPyridopyrimidine derivatives as agents | 奇斯药制品公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-110092781-A | A kind of novel quinazoline quinoline class EGFR inhibitor and its preparation and application | 河南省医药科学研究院 | 2019-08-06 | — | — | CN | disclosed |
| US-5667949-A | PHOTOGRAPHIC FILM SUPPORTS WITH SILVER HALIDE EMULSIONS WITH STABILIZERS AND DEVELOPMENT WITH BROMIDE IONS | EASTMAN KODAK COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| WO-1997021711-A1 | PROCESS FOR PREPARING 4-AMINOPTERIDINE DERIVATIVES | LONZA AG (CH) | 1997-06-19 | — | — | WO | disclosed |
| EP-0770907-A1 | Photographic material and process utilizing high chloride tabular grain silver halide emulsions with (111) crystallographic faces | EASTMAN KODAK COMPANY (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0399856-B1 | Pteridin-4 (3H)-ones, processes for their preparation and medicaments containing them | LIPHA (FR) | 1995-08-09 | — | — | EP | disclosed |
| US-5270465-A | 4(3H)-pteridinone compounds | LIPHA, LYONNAISE INDUSTRILLE PHARMACEUTIQUE (FR) | 1993-12-14 | — | — | US | disclosed |
| US-5167949-A | Antiallergic | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1992-12-01 | — | — | US | disclosed |
| EP-0399856-A1 | Pteridin-4 (3H)-ones, processes for their preparation and medicaments containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1990-11-28 | — | — | EP | disclosed |
| US-4187307-A | 4-AMINOPTERIDINES | ABBOTT LABORATORIES (US) | 1980-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | CBR1, CBR3, COX6C | ADORA2A 2080/4885PI4KA 3988/4885PI4K2B 3435/4885 |
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | ADORA2A 53/4885PI4KA 662/4885PI4K2B 926/4885 |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX2 | ADORA2A 71/4885PI4KA 971/4885PI4K2B 973/4885 |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | P2RX5, PNPO, P2RX3 | ADORA2A 2030/4885PI4KA 2418/4885PI4K2B 2156/4885 |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | ADORA2A 53/4885PI4KA 662/4885PI4K2B 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.